Compare PMN & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PMN | BNR |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | Canada | China |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.5M | 119.2M |
| IPO Year | 2022 | 2019 |
| Metric | PMN | BNR |
|---|---|---|
| Price | $15.27 | $9.56 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $42.67 | N/A |
| AVG Volume (30 Days) | ★ 55.9K | 23.0K |
| Earning Date | 05-13-2026 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $111.65 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $4.75 |
| 52 Week High | $27.40 | $41.72 |
| Indicator | PMN | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 67.94 | 46.01 |
| Support Level | $8.79 | $8.00 |
| Resistance Level | $19.85 | $10.00 |
| Average True Range (ATR) | 1.30 | 0.96 |
| MACD | 0.15 | 0.16 |
| Stochastic Oscillator | 90.79 | 31.06 |
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.